HIV AIDS Pkiprint
HIV AIDS Pkiprint
HIV AIDS Pkiprint
HIV/AIDS
19 July 2018
Key facts
HIV continues to be a major global public health issue, having claimed more than 35 million
lives so far. In 2017, 940 000 people died from HIV-related causes globally.
There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8
million people becoming newly infected in 2017 globally.
59% of adults and 52% of children living with HIV were receiving lifelong antiretroviral
therapy (ART) in 2017.
Global ART coverage for pregnant and breastfeeding women living with HIV is high at 80%.
The WHO African Region is the most affected region, with 25.7 million people living with HIV
in 2017. The African region also accounts for over two thirds of the global total of new HIV
infections.
HIV infection is often diagnosed through rapid diagnostic tests (RDTs), which detect the
presence or absence of HIV antibodies. Most often these tests provide same-day test
results, which are essential for same day diagnosis and early treatment and care.
Key populations are groups who are at increased risk of HIV irrespective of epidemic type or
local context. They include: men who have sex with men, people who inject drugs, people in
prisons and other closed settings, sex workers and their clients, and transgender people.
Key populations often have legal and social issues related to their behaviours that increase
vulnerability to HIV and reduce access to testing and treatment programmes.
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 1/10
8/31/2018 HIV/AIDS
In 2017, an estimated 47% of new infections occurred among key populations and their
partners.
There is no cure for HIV infection. However, effective antiretroviral (ARV) drugs can control
the virus and help prevent transmission so that people with HIV, and those at substantial
risk, can enjoy healthy, long and productive lives.
It is estimated that currently only 75% of people with HIV know their status. In 2017, 21.7
million people living with HIV were receiving antiretroviral therapy (ART) globally.
Between 2000 and 2017, new HIV infections fell by 36%, and HIV-related deaths fell by 38%
with 11.4 million lives saved due to ART in the same period. This achievement was the result
of great efforts by national HIV programmes supported by civil society and a range of
development partners.
The Human Immunodeficiency Virus (HIV) targets the immune system and weakens people's defence
systems against infections and some types of cancer. As the virus destroys and impairs the function of
immune cells, infected individuals gradually become immunodeficient. Immune function is typically
measured by CD4 cell count.
Immunodeficiency results in increased susceptibility to a wide range of infections, cancers and other
diseases that people with healthy immune systems can fight off.
The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can
take from 2 to 15 years to develop depending on the individual. AIDS is defined by the development of
certain cancers, infections, or other severe clinical manifestations.
As the infection progressively weakens the immune system, an individual can develop other signs and
symptoms, such as swollen lymph nodes, weight loss, fever, diarrhoea and cough. Without treatment,
they could also develop severe illnesses such as tuberculosis, cryptococcal meningitis, severe
bacterial infections and cancers such as lymphomas and Kaposi's sarcoma, among others.
Transmission
HIV can be transmitted via the exchange of a variety of body fluids from infected individuals, such as
blood, breast milk, semen and vaginal secretions. Individuals cannot become infected through
ordinary day-to-day contact such as kissing, hugging, shaking hands, or sharing personal objects,
food or water.
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 2/10
8/31/2018 HIV/AIDS
Risk factors
Behaviours and conditions that put individuals at greater risk of contracting HIV include:
Diagnosis
Serological tests, such as RDTs or enzyme immunoassays (EIAs), detect the presence or absence of
antibodies to HIV-1/2 and/or HIV p24 antigen. No single HIV test can provide an HIV-positive
diagnosis. It is important that these tests are used in combination and in a specific order that has been
validated and is based on HIV prevalence of the population being tested. HIV infection can be
detected with great accuracy, using WHO prequalified tests within a validated approach.
It is important to note that serological tests detect antibodies produced by an individual as part of their
immune system to fight off foreign pathogens, rather than direct detection of HIV itself.
Most individuals develop antibodies to HIV within 28 days of infection and therefore antibodies may
not be detectable early, during the so-called window period. This early period of infection represents
the time of greatest infectivity; however HIV transmission can occur during all stages of the infection.
It is best practice to also retest all people initially diagnosed as HIV-positive before they enroll in care
and/or treatment to rule out any potential testing or reporting error. Notably, once a person diagnosed
with HIV and has started treatment they should not be retested.
Testing and diagnosis of HIV-exposed infants has been a challenge. For infants and children less than
18 months of age, serological testing is not sufficient to identify HIV infection – virological testing must
be provided (at 6 weeks of age, or as early as birth) to detect the presence of the virus in infants born
to mothers living with HIV. However, new technologies are now becoming available to perform the test
at the point of care and enable return of the result on the same day to accelerate appropriate linkage
and treatment initiation.
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 3/10
8/31/2018 HIV/AIDS
New technologies to help people test themselves are being introduced, with many countries
implementing self-testing as an additional option to encourage HIV diagnosis. HIV self-testing is a
process whereby a person who wants to know his or her HIV status collects a specimen, performs a
test and interprets the test results in private or with someone they trust. HIV self-testing does not
provide a definitive HIV-positive diagnosis – instead, it is an initial test which requires further testing by
a health worker.
The sexual partners and drug injecting partners of people diagnosed with HIV infection have an
increased probability of also being HIV-positive. WHO recommends assisted HIV partner notification
services as a simple and effective way to reach these partners, many of whom are undiagnosed and
unaware of their HIV exposure, and may welcome support and an opportunity to test for HIV.
All HIV testing services must follow the 5 Cs principles recommended by WHO:
informed Consent
Confidentiality
Counselling
Correct test results
Connection (linkage to care, treatment and other services).
Prevention
Individuals can reduce the risk of HIV infection by limiting exposure to risk factors. Key approaches for
HIV prevention, which are often used in combination, are listed below.
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 4/10
8/31/2018 HIV/AIDS
Early detection of TB and prompt linkage to TB treatment and ART can prevent these deaths. TB
screening should be offered routinely at HIV care services and routine HIV testing should be offered to
all patients with presumptive and diagnosed TB. Individuals who are diagnosed with HIV and active
TB should urgently start effective TB treatment (including for multidrug resistant TB) and ART. TB
preventive therapy should be offered to all people with HIV who do not have active TB.
A 2011 trial has confirmed that if an HIV-positive person adheres to an effective ART regimen, the risk
of transmitting the virus to their uninfected sexual partner can be reduced by 96%. The WHO
recommendation to initiate ART in all people living with HIV will contribute significantly to reducing HIV
transmission.
Oral PrEP of HIV is the daily use of ARV drugs by HIV-negative people to block the acquisition of HIV.
More than 10 randomized controlled studies have demonstrated the effectiveness of PrEP in reducing
HIV transmission among a range of populations including serodiscordant heterosexual couples (where
one partner is infected and the other is not), men who have sex with men, transgender women, high-
risk heterosexual couples, and people who inject drugs.
WHO recommends PrEP as a prevention choice for people at substantial risk of HIV infection as part
of a combination of prevention approaches. WHO has also expanded these recommendations to HIV-
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 5/10
8/31/2018 HIV/AIDS
Post-exposure prophylaxis (PEP) is the use of ARV drugs within 72 hours of exposure to HIV in order
to prevent infection. PEP includes counselling, first aid care, HIV testing, and administration of a 28-
day course of ARV drugs with follow-up care. WHO recommends PEP use for both occupational and
non-occupational exposures and for adults and children.
WHO recommends lifelong ART for all people living with HIV, regardless of their CD4 count clinical
stage of disease, and this includes women who pregnant or breastfeeding. In 2017, 80% of the
estimated 1.1 million pregnant women living with HIV globally received ARV treatments to prevent
transmission to their children. A growing number of countries are achieving very low rates of MTCT
and some (Armenia, Belarus, Cuba and Thailand) have been formally validated for elimination of
MTCT of HIV as a public health problem. Several countries with a high burden of HIV infection are
also progressing along the path to elimination.
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 6/10
8/31/2018 HIV/AIDS
Treatment
HIV can be suppressed by combination ART consisting of 3 or more ARV drugs. ART does not cure
HIV infection but suppresses viral replication within a person's body and allows an individual's immune
system to strengthen and regain the capacity to fight off infections.
In 2016, WHO released the second edition of the Consolidated guidelines on the use of antiretroviral
drugs for treating and preventing HIV infection. These guidelines recommend to provide lifelong ART
to all people living with HIV, including children, adolescents and adults, pregnant and breastfeeding
women, regardless of clinical status or CD4 cell count. By mid-2018, 163 countries already have
adopted this recommendation, which covers 98% of all PLHIV globally.
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
The 2016 guidelines include new alternative ARV options with better tolerability, higher efficacy, and
lower rates of treatment discontinuation when compared with medicines being used currently:
dolutegravir and low-dose efavirenz for first-line therapy, and raltegravir and darunavir/ritonavir for
second-line therapy.
Transition to dolutegravir has already started in 24 low- and middle-income countries and is expected
to improve the durability of the treatment and the quality of care of people living with HIV. Despite
improvements, limited options remain for infants and young children. For this reason, WHO and
partners are coordinating efforts to enable a faster and more effective development and introduction of
age-appropriate pediatric formulations of antiretrovirals.
In addition, 1 in 3 people living with HIV present to care with advanced disease, at low CD4 counts
and at high risk of serious illness and death. To reduce this risk, WHO recommends that these patients
receive a “package of care” that includes testing for and prevention of the most common serious
infections that can cause death, such as tuberculosis and cryptococcal meningitis, in addition to ART.
Based on WHO’s new recommendations to treat all people living with HIV, the number of people
eligible for ART has increased from 28 million to all 36.9 million people living with HIV.
In 2017, 21.7 million people living with HIV were receiving ART globally. In 2017, a global ART
coverage of 59% of adults and children living with HIV was reached. However, more efforts are
needed to scale up treatment, particularly for children and adolescents. Only 52% of them were
receiving ARVs at the end of 2017 and WHO is supporting countries to accelerate their efforts to
timely diagnose and treat these vulnerable populations.
Expanding access to treatment is at the heart of a set of targets for 2020 which aim to bring the world
on track to end the AIDS epidemic by 2030.
WHO response
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 7/10
8/31/2018 HIV/AIDS
The Sixty-ninth World Health Assembly endorsed a new Global Health Sector Strategy on HIV for
2016-2021. The strategy includes 5 strategic directions that guide priority actions by countries and by
WHO over the next six years.
WHO is a cosponsor of the Joint United Nations Programme on AIDS (UNAIDS). Within UNAIDS,
WHO leads activities on HIV treatment and care, HIV and tuberculosis co-infection, and jointly
coordinates with UNICEF the work on the elimination of mother-to-child transmission of HIV.
Related
News
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 8/10
8/31/2018 HIV/AIDS
Fact sheets
Facts in pictures
HIV/AIDS
19 July 2018
Feature stories
Commentaries
About us
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 9/10
8/31/2018 HIV/AIDS
Quick links
Regions
© 2018 WHO
http://www.who.int/news-room/fact-sheets/detail/hiv-aids 10/10